Abstract
Preclinical and clinical studies conducted in the mid-1990s reported strong association and causality between the T-cell helper (TH) 1 inductor cytokine interleukin (IL)-12 and numerous immune-mediated disorders, which spurred the development of therapeutic agents targeting IL-12 function. One of the first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 subunit of IL-12. Subsequent to the generation of ustekinumab, it was discovered that IL-23 also contains the p40 subunit. Thus, although ustekinumab was designed to target IL-12, it also modulates IL-23, a cytokine important to the development and/or maintenance of TH17 cells. Clinical observations established that IL-12/23p40 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease. The molecular and cellular evaluations conducted in ustekinumab clinical programs have provided numerous insights into the pathologic processes of these disorders, illustrating how a novel molecular entity can contribute to our understanding of disease. The individual contributions of these cytokines to specific pathologies require investigation and clinical evaluation of the role of IL-12– and IL-23–specific inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. & Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348–2357 (1986).
Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).
Fiorentino, D.F., Bond, M.W. & Mosmann, T.R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081–2095 (1989).
Kobayashi, M. et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827–845 (1989).
Presky, D.H. et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93, 14002–14007 (1996).
Hong, K., Chu, A., Lúdvíksson, B.R., Berg, E.L. & Ehrhardt, R.O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162, 7480–7491 (1999).
Leonard, J.P., Waldburger, K.E. & Goldman, S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181, 381–386 (1995).
Yawalkar, N., Karlen, S., Hunger, R., Brand, C.U. & Braathen, L.R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111, 1053–1057 (1998).
Davidson, N.J. et al. IL-12 but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10 deficient mice. J. Immunol. 161, 3143–3149 (1998).
Malfait, A.M. et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111, 377–383 (1998).
Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112, 1169–1178 (1997).
Berrebi, D. et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am. J. Pathol. 152, 667–672 (1998).
Windhagen, A. et al. Expression of costimulatory molecules B7–1 (Crohn's disease80), B7–2 (Crohn's disease86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985–1996 (1995).
van Boxel-Dezaire, A.H. et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45, 695–703 (1999).
Nicoletti, F. et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol. 70, 87–90 (1996).
Fassbender, K. et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 51, 753–758 (1998).
Fishwild, D.M. et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845–851 (1996).
Luo, J. et al. Structural basis for dual recognition of IL-12 and IL-23 by ustekinumab. J. Mol. Biol. 402, 797–812 (2010).
Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715–725 (2000).
Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002).
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F.J. & Gurney, A.L. Interleukin-23 promotes a distinct Crohn's disease4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003).
Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).
Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942–949 (2007).
Wilson, N.J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950–957 (2007).
Trifari, S., Kaplan, C.D., Tran, E.H., Crellin, N.K. & Spits, H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10, 864–871 (2009).
Staudt, V. et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33, 192–202 (2010).
Murphy, K.M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11, 674–680 (2010).
Zhou, L., Chong, M.M. & Littman, D.R. Plasticity of Crohn's disease4+ T cell lineage differentiation. Immunity 30, 646–655 (2009).
Curtis, M.M., Way, S.S. & Wilson, C.B. IL-23 promotes production of IL-17 by antigen-specific CD8 by CD T cells in the absence of IL-12 and type-I interferons. J. Immunol. 183, 381–387 (2009).
van de Wetering, D., de Paus, R.A. & van Dissel, J.T. & van de Vosse, E. IL-23 modulates Crohn's disease56+/Crohn's disease3- NK cell and Crohn's disease56+/Crohn's disease3+ NK-like T cell function differentially from IL-12. Int. Immunol. 21, 145–153 (2008).
Murphy, C.A. et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951–1957 (2003).
Gran, B. et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169, 7104–7110 (2002).
Cua, D.J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003).
Torti, D.C. & Feldman, S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57, 1059–1068; comment and author reply. 58, 1083 (2007).
Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290 (2007).
Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201–206 (2007).
Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
Di Meglio, P. et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector responses in humans. PLoS ONE 6, e17160 (2011).
Sachs, C. et al. Characterization of immune and asthmatic responses in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). The Toxicologist 102, Abstract 2141 (2008).
Gottlieb, A.B. & Dann, F. Comorbidities in patients with psoriasis. Am. J. Med. 122, 1150e1–1150e9 (2008).
Martin, P.L. et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res. 83, 1–13 (2010).
Naz, R.K. & Evans, L. Presence and modulation of interleukin-12 in seminal plasma of fertile and infertile men. J. Androl. 19, 302–307 (1998).
Buse, E., Habermann, G., Osterburg, I., Korte, R. & Weinbauer, G.F. Reproductive/ developmental toxicity and immunogenicity assessment in the nonhuman primate model. Toxicology 221, 221–227 (2003).
Toichi, E. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917–4926 (2006).
Kauffman, C.L. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037–1044 (2004).
Fredriksson, T. & Pettersson, U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157, 238–244 (1978).
Krueger, G.G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
Zhu, Y. et al. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of CNTO 1275 in subjects with moderate to severe psoriasis vulgaris. J. Clin. Pharmacol. 47, 1203, Abstract 90 (2007).
Zhou, H. et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 50, 257–267 (2010).
Wang, W., Wang, E.Q. & Balthasar, J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548–558 (2008).
Ghetie, V. & Ward, E.S. Transcytosis and catabolism of antibody. Immunol. Res. 25, 97–113 (2002).
Zhu, Y., Mendelsohn, A., Pendley, C., Davis, H.M. & Zhou, H. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int. J. Clin. Pharmacol. Ther. 48, 830–846 (2010).
Zhu, Y. et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49, 162–175 (2009).
Sandborn, W.J. et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130–1141 (2008).
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009); errata in 373, 1340 (2009) and 376, 1542 (2010).
Segal, B.M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796–804 (2008).
Zhou, H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J. Clin. Pharmacol. 46, 1268–1289 (2006).
Zhou, H. & Davis, H.M. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14, 891–898 (2009).
Reddy, M. et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J. Dermatol. 37, 413–425 (2010).
Nestle, F.O. et al. Psoriasis. N. Engl. J. Med. 361, 496–509 (2009).
Looney, R.J. et al. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin. Immunol. 123, 235–243 (2007).
Brodmerkel, C. et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J. Drugs Dermatol. 9, 677–683 (2010).
Leonardi, C.L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008); erratum in: 1838 (2008).
Griffiths, C.E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
Papp, K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).
Schellekens, H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24, 1720–1740 (2002); discussion 1719 (2002).
Lowes, M.A. et al. Pathogenesis and therapy of psoriasis. Nature 445, 866–873 (2007).
Shigehara, K. et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol. 166, 642–649 (2001).
Judson, M. et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of IL-12, IL-23, and the Th17 pathways. J. Amer. Acad. Derm. (in the press).
Bowman, E.P., Chackerian, A.A. & Cua, D.J. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 19, 245–252 (2006).
Torti, D.C. & Feldman, S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57, 1059–1068 (2007).
Airoldi, I. et al. Lack of IL12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106, 3846–3853 (2005).
Street, S.E., Trapani, J.A., MacGregor, D. & Smyth, M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196, 129–134 (2002).
Leonard, J.P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541–2548 (1997).
Portielje, J.E. et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5, 3983–3989 (1999).
Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T-cell-mediated tissue damage. Nat. Med. 13, 139–145 (2007).
Laurence, A. & O'Shea, J.J. T(H)-17 differentiation: of mice and men. Nat. Immunol. 8, 903–905 (2007).
Novelli, F. & Casanova, J.L. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev. 15, 367–377 (2004).
Fieschi, C. & Casanova, J.L. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur. J. Immunol. 33, 1461–1464 (2003).
Filipe-Santos, O. et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18, 347–361 (2006).
Cárdenes, M. et al. Oesophageal squamous cell carcinoma in a young adult with Il-12Rβ1 deficiency. J. Med. Genet. 47, 635–637 (2010).
Gottlieb, A.B. et al. A phase I double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23, 1081–1092 (2007).
Kasper, L.H. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr. Med. Res. Opin. 22, 1671–1678 (2006).
Dillon, S.R. New mechanisms and expanded indications for biologic therapies: a perspective on immunology research and development. Drug Disc. World Fall, 87–93 (2010).
Acknowledgements
The authors want to thank M. Curran and M. Whitman for their critical review and insightful comments on manuscript content, and B. Loux for graphic development.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.M. is an independent biopharmaceutical consultant under contract with Centocor/Orthobiotech – the developers of ustekinumab.
Rights and permissions
About this article
Cite this article
Benson, J., Sachs, C., Treacy, G. et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 29, 615–624 (2011). https://doi.org/10.1038/nbt.1903
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1903
This article is cited by
-
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Nature Biotechnology (2020)
-
Comprehensive expression patterns of inflammatory cytokines in aqueous humor of patients with neovascular age-related macular degeneration
Scientific Reports (2019)
-
The molecular basis of chaperone-mediated interleukin 23 assembly control
Nature Communications (2019)
-
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Nature Reviews Immunology (2018)
-
Quetiapine ameliorates collagen-induced arthritis in mice via the suppression of the AKT and ERK signaling pathways
Inflammation Research (2018)